MeiraGTx Holdings plc
MGTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MGTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MGTX
MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company focused on developing gene therapies for diseases including radiation-induced xerostomia, Sjögren's syndrome, and Parkinson's disease, with no product revenues to date and a history of significant operating losses.
Key risk: No product revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.33B
Cash Runway
13.0 moLead Asset
aav-aipl1 (Preclinical)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 catalyst for MeiraGTx Holdings plc.
MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company focused on developing gene therapies for diseases including radiation-induced xerostomia, Sjögren's syndrome, and Parkinson's disease, with no product revenues to date and a history of significant operating losses.
- Vertically integrated, clinical-stage genetic medicines company with programs in AAV-hAQP1 (xerostomia) and AAV-GAD (Parkinson's disease) [sec_mda · as of 2026-08-13].
- Reported net income of $160.7M for the three months ended June 30, 2026, but an accumulated deficit of $701.8M as of the same date [sec_mda · as of 2026-08-13].
- Cash, cash equivalents and restricted cash of $73.8M as of March 31, 2026, with additional financing expected in Q3 2026 [sec_mda · as of 2026-05-14].
- No product revenues generated to date; relies on collaboration, license, and asset purchase agreements for funding [sec_mda · as of 2026-08-13].
- Expects significant future expenses for clinical trials, manufacturing, and pipeline expansion [sec_mda · as of 2026-05-14].
What works
- Vertically integrated platform may provide control over manufacturing and development processes [sec_mda · as of 2026-08-13].
- Reported net income of $160.7M in Q2 2026, partly from collaboration and asset purchase agreements [sec_mda · as of 2026-08-13].
- Multiple clinical programs targeting large unmet needs (xerostomia, Parkinson's) [sec_mda · as of 2026-08-13].
What to weigh
- No product revenues to date; accumulated deficit of $701.8M as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Cash used in operations was $93.0M for the nine months ended September 30, 2025, with no assurance of positive cash flows [sec_mda · as of 2025-11-13].
- Dependence on external financing to continue operations; may need to delay or reduce programs if capital is insufficient [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Company is clinical-stage with no product revenues
“We are a clinical stage company and have not generated any product revenues to date.”
SEC MD&A · August 13, 2026
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $701.8 million.”
SEC MD&A · August 13, 2026
Net income for Q2 2026
“Our net income for the three-month period ended June 30, 2026 and net loss for the three-month period ended June 30, 2025 were $160.7 million and $38.8 million, respectively.”
SEC MD&A · August 13, 2026
Cash position as of March 31, 2026
“As of March 31, 2026, we had cash, cash equivalents and restricted cash of $73.8 million”
SEC MD&A · May 14, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · aav-haqp1 — Phase 2 Readout: aav-haqp1 — Topline data from the Phase 2 trial of AAV-hAQP1 for radiation-induced xerostomia is expected by the end of 2026.
Risks & what to watch (4)›
Key risks
- No product revenue — Company has not generated any product revenue to date and relies on external funding [sec_mda · as of 2026-08-13].
- Significant accumulated deficit — Accumulated deficit of $701.8M as of June 30, 2026, with ongoing operating losses [sec_mda · as of 2026-08-13].
- Cash burn and financing need — Used $93.0M in operations in nine months ended Sep 30, 2025; may need to raise additional capital [sec_mda · as of 2025-11-13].
- Clinical-stage uncertainty — All product candidates are in clinical or preclinical stages; regulatory approval uncertain [sec_mda · as of 2026-08-13].
What to watch
- Phase 2 topline data for AAV-hAQP1 in radiation-induced xerostomia expected by end of 2026 [catalyst].
- Ability to secure additional financing to support ongoing operations and clinical trials [sec_mda · as of 2026-08-13].
- Progress of AAV-GAD for Parkinson's disease and other pipeline programs [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run MeiraGTx Holdings plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MeiraGTx Holdings plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
13.0 months
OCF -$39M · Net income $161M
Lead: Phase 1
4 candidates
1 upcoming, next in ~123d
0 buys · 8 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
130
Total value held
$489.8M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 20,652,206 | $178.6M |
| johnson & johnson | 6,641,064 | $57.5M |
| adage capital partners gp, l.l.c. | 4,000,000 | $34.6M |
| millennium management llc | 3,465,699 | $30.0M |
| blackrock, inc. | 3,168,148 | $27.4M |
| prosight management, lp | 2,629,971 | $22.8M |
| 683 capital management, llc | 2,450,000 | $21.2M |
| morgan stanley | 1,589,940 | $13.8M |
| knoll capital management, llc | 1,250,000 | $10.8M |
| kennedy capital management llc | 858,379 | $7.4M |
Showing top 10 of 130 institutional holders of MeiraGTx Holdings plc. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 8.8%
- Days to cover
- 5.1
- Shares short
- 5,731,677
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MGTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for MeiraGTx Holdings plc?
MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company focused on developing gene therapies for diseases including radiation-induced xerostomia, Sjögren's syndrome, and Parkinson's disease, with no product revenues to date and a history of significant operating losses.
What is MeiraGTx Holdings plc's lead drug candidate?
MeiraGTx Holdings plc's most advanced tracked candidate is aav-aipl1 (Preclinical) for Leber congenital amaurosis 4 (LCA4).
What is MeiraGTx Holdings plc's next catalyst?
MeiraGTx Holdings plc's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: aav-haqp1" — expected December 31, 2026.
Who is the CEO of MeiraGTx Holdings plc?
Dr. Alexandria Forbes Ph.D. is the chief executive officer of MeiraGTx Holdings plc (MGTX).
Where is MeiraGTx Holdings plc headquartered?
MeiraGTx Holdings plc (MGTX) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.